A novel phenotypic expression associated with a new mutation in LMNA gene, characterized by partial lipodystrophy, insulin-resistance, aortic stenosis and hypertrophic cardiomyopathy.

Background: Lipodystrophies are a heterogeneous group of diseases characterized by abnormal fat distribution. Familial partial lipodystrophy 2 (FPLD2) is due to mutations in the LMNA gene. Previous studies have suggested that LMNA mutations 5’to the nuclear localization signal (NLS) are more likely to underlie laminopathies with cardiac or skeletal muscle involvement, while mutations 3’ to the NLS are more likely to underlie lipodystrophy and progeroid syndromes. Objective: To study the clinical and molecular features of a subject with FPLD. Subjects and Methods: We carry out mutational analysis of LMNA gene in a woman with FPLD phenotype and in her relatives. Insulin resistance was evaluated by minimal model. Body composition was evaluated by DEXA. Echocardiography was done in affected subjects. 3T3-L1 preadipocytes were transfected with wild-type or mutant pre-lamin A constructs. In transfected cells, lamin A was detected using a Cy3-conjugated monoclonal anti-FLAG antibody (Sigma, M2). Results: The patient showed atypical fat distribution, insulin resistance, severe aortic stenosis, and hypertrophic cardiomyopathy. She has an affected 11-year-old son, not yet lipodystrophic but with an incipient aortic disease. LMNA sequencing showed that mother and son were both heterozygous for a novel c.1772G>T missense mutation in exon 11, which causes the substitution of the cysteine at residue 591 by a phenylalanine (C591F). In mouse preadipocytes transfected with the mutant human LMNA gene, the mutant lamin A isoform was mislocated in the nucleus. Conclusions: This patient shows a novel clinical form of FPLD2, due to a mutation affecting lamin A only, with cardiac involvement.